Cargando…
Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
Purpose Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/ https://www.ncbi.nlm.nih.gov/pubmed/37969671 http://dx.doi.org/10.1055/s-0042-1753478 |
_version_ | 1785146360298733568 |
---|---|
author | Kapoor, Akhil Noronha, Vanita Patil, Vijay Menon, Nandini Nandhana, Ravindra Kumar, Amit Mahajan, Abhishek Janu, Amit Kumar, Rajiv Prabhash, Kumar |
author_facet | Kapoor, Akhil Noronha, Vanita Patil, Vijay Menon, Nandini Nandhana, Ravindra Kumar, Amit Mahajan, Abhishek Janu, Amit Kumar, Rajiv Prabhash, Kumar |
author_sort | Kapoor, Akhil |
collection | PubMed |
description | Purpose Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data about the long-term efficacy and toxicity of crizotinib is limited. Methods A retrospective analysis of all patients with ALK-positive NSCLC, treated with crizotinib between March 2014 and December 2016, was performed. The main outcomes measured were PFS, overall survival (OS), and adverse effects. Results One hundred and eighty-eight patients treated with crizotinib during this period were included in this study. The median age was 50 years (range: 24–74) with a majority being males (73.2%) and 80.3% with a performance status of 0 to 1. The median duration of follow-up was 49.4 months (range: 3.4–86.3%). The median PFS of crizotinib was 17.3 months (95% confidence interval [CI], 13.0–21.6) and 12.8 months (95% CI, 8.1–17.6) when used in first line or subsequent lines, respectively. The median OS was 38.3 months (95% CI, 28.4–48.2). The patients who received crizotinib in the first line had a median OS of 45.5 months (95% CI, 29.6–61.4) as compared with 29.7 months (95% CI, 22.2–37.2) for those who received in subsequent line (hazard ratio, 0.6, 95% CI, 0.4–0.9, p =0.022). The most common all grade toxicities include transaminitis, anemia, fatigue, and corrected QT prolongation. Conclusion This real-world study confirms the long-term beneficial effects of crizotinib in ALK rearranged NSCLC with favorable toxicity profile like that of the registration studies, in resource constrained settings. |
format | Online Article Text |
id | pubmed-10635771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106357712023-11-15 Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings Kapoor, Akhil Noronha, Vanita Patil, Vijay Menon, Nandini Nandhana, Ravindra Kumar, Amit Mahajan, Abhishek Janu, Amit Kumar, Rajiv Prabhash, Kumar South Asian J Cancer Purpose Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data about the long-term efficacy and toxicity of crizotinib is limited. Methods A retrospective analysis of all patients with ALK-positive NSCLC, treated with crizotinib between March 2014 and December 2016, was performed. The main outcomes measured were PFS, overall survival (OS), and adverse effects. Results One hundred and eighty-eight patients treated with crizotinib during this period were included in this study. The median age was 50 years (range: 24–74) with a majority being males (73.2%) and 80.3% with a performance status of 0 to 1. The median duration of follow-up was 49.4 months (range: 3.4–86.3%). The median PFS of crizotinib was 17.3 months (95% confidence interval [CI], 13.0–21.6) and 12.8 months (95% CI, 8.1–17.6) when used in first line or subsequent lines, respectively. The median OS was 38.3 months (95% CI, 28.4–48.2). The patients who received crizotinib in the first line had a median OS of 45.5 months (95% CI, 29.6–61.4) as compared with 29.7 months (95% CI, 22.2–37.2) for those who received in subsequent line (hazard ratio, 0.6, 95% CI, 0.4–0.9, p =0.022). The most common all grade toxicities include transaminitis, anemia, fatigue, and corrected QT prolongation. Conclusion This real-world study confirms the long-term beneficial effects of crizotinib in ALK rearranged NSCLC with favorable toxicity profile like that of the registration studies, in resource constrained settings. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-09-02 /pmc/articles/PMC10635771/ /pubmed/37969671 http://dx.doi.org/10.1055/s-0042-1753478 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Kapoor, Akhil Noronha, Vanita Patil, Vijay Menon, Nandini Nandhana, Ravindra Kumar, Amit Mahajan, Abhishek Janu, Amit Kumar, Rajiv Prabhash, Kumar Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title | Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title_full | Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title_fullStr | Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title_full_unstemmed | Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title_short | Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings |
title_sort | long-term outcomes of crizotinib treated alk-positive lung cancer patients: a retrospective audit of prospective data from resource-constrained settings |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/ https://www.ncbi.nlm.nih.gov/pubmed/37969671 http://dx.doi.org/10.1055/s-0042-1753478 |
work_keys_str_mv | AT kapoorakhil longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT noronhavanita longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT patilvijay longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT menonnandini longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT nandhanaravindra longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT kumaramit longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT mahajanabhishek longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT januamit longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT kumarrajiv longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings AT prabhashkumar longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings |